EUSA Pharma, a British pharmaceutical company specializing in rare diseases, announced its full-fledged entry into the Korean market. EUSA Pharma plans to directly supply the existing domestic approved Castlemans disease treatment, Sylvant (Siltuximab), while also accelerating the introduction of new rare disease treatments.

EUSA Pharma held a press conference at The Plaza in Seoul on the 13th and announced its ambition to improve its recognition of Castlemans danger and enter the Korean market. EUSA Pharma is a pharmaceutical company specializing in rare diseases established in the UK in 2015. It was established as EW Healthcare Partners Funding, an investment company specializing in life science. As of J